- Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
- Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, Richard AC, Brenner O, Lahouegue A, Freyer G, Floquet A, Frank S, Kfoury M.
- Drugs Real World Outcomes. 2023 Jan 11. doi: 10.1007/s40801-022-00349-9. Epub ahead of print.
- PMID: 36630055
- PubMed abstract
- A Glance at Molecular Advances in Cancer Genetics: A Baffling Puzzle Still to Be Solved.
- Ghiorzo P, Bruno W.
- Int J Mol Sci. 2023 Jan 11;24(2):1394. doi: 10.3390/ijms24021394.
- Review
- Free Full Text
- Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom [Clinically relevant molecular pathological diagnostics in breast cancer].
- Rodepeter FR, Teply-Szymanski J, Romey M, Grass A, Erber R, Lebeau A, Mack EKM, Tarawneh TS, Gremke N, Boekhoff J, Wündisch T, Wagner U, Jank P, Denkert C.
- Pathologie (Heidelb). 2023 Jan 11. German. doi: 10.1007/s00292-022-01175-0. Epub ahead of print.
- PMID: 36629894
- PubMed abstract
- Source abstract
- Review. [Article in German]
- Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC.
- Dorff TB.
- OncLive. OncLive TV. 2023 Jan 10.
- Research news. Video.
- Free Full Text
- An international, multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes.
- Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim DK, Lim S, Martin E, FRENEL JS, Bocquet F, Kubelac P, Achimas-Cadariu P, Vlad C, Chevrier M, Rouzier R, Carton M, Savva-Bordalo J, Magalhães M, Borges M, Wolf A, Becker S, Niklas N, Guergova-Kuras M, Hall G.
- Front Oncol. 2023 Jan 9;12:1114435. doi: 10.3389/fonc.2023.1114435.
- Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China.
- Wang DF, Shi XW, Zhang C, Zhang J, Liu H, Huang JM, Zhang GN, Wen QL.
- Gynecol Oncol. 2023 Jan 4;170:25-31. doi: 10.1016/j.ygyno.2022.12.014. Epub ahead of print.
- PMID: 36608384
- PubMed abstract
- Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish Expanded-Access Programme.
- Cueva JF, Palacio I, Churruca C, Herrero A, Pardo B, Constenla M, Santaballa A, Manso L, Estévez P, Maximiano C, Legerén M, Marquina G, de Juan A, Quindós M, Sánchez L, Barquin A, Fernández I, Martín C, Juárez A, Martín T, García Y, Yubero A, Gallego A, Martínez Bueno A, Guerra E, González-Martín A.
- Eur J Cancer. 2023 Jan 1. doi: 10.1016/j.ejca.2022.12.023. Epub ahead of print.
•• Identifier: NCT04546373: Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)
- Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
- Shu T, Zhou Z, Bai J, Xiao X, Gao M, Zhang N, Wang H, Xia X, Gao Y, Zheng H.
- Gynecol Oncol. 2023 Jan;168:135-143. doi: 10.1016/j.ygyno.2022.11.013. Epub 2022 Nov 25.
- PMID: 36442424
- PubMed abstract
- Ferroptosis synergistically sensitizes wee1 inhibitors: a bibliometric study.
- Xu R, Wu X, Zhao Q, Yang Q.
- Am J Transl Res. 2022 Dec 15;14(12):8473-8488.
- PMID: 36628201
- PubMed abstract
- ToC
- Bibliometric analysis
- Free PMC article
- Free Full Text (PDF)
- Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia.
- Olaya J, Sanjuan J, Torres-Lopez D, Olaya L, Gutierrez-Vargas M, Olaya G, Olaya JD.
- Cureus. 2022 Dec 6;14(12):e32257. doi: 10.7759/cureus.32257.
- PMID: 36620844
- PubMed abstract